Principles of Pharmacogenetics and Pharmacogenomics
Herausgeber: Altman, Russ B.; Goldstein, David B.; Flockhart, David
Principles of Pharmacogenetics and Pharmacogenomics
Herausgeber: Altman, Russ B.; Goldstein, David B.; Flockhart, David
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This textbook presents the latest information on pharmacogenetics and pharmacogenomics for students, professionals and researchers.
Andere Kunden interessierten sich auch für
- Kewal K. JainTextbook of Personalized Medicine115,99 €
- Concepts and Principles of Pharmacology125,99 €
- Clinical Pharmacology During Pregnancy86,99 €
- Arwa Mohamed Amin MostafaClopidogrel Personalization: Pharmacogenetics and Pharmacometabonomics32,99 €
- Alex A. AdjeiNovel Anticancer Agents224,99 €
- Handbook of Anticancer Pharmacokinetics and Pharmacodynamics184,99 €
- Handbook of Anticancer Pharmacokinetics and Pharmacodynamics184,99 €
-
-
-
This textbook presents the latest information on pharmacogenetics and pharmacogenomics for students, professionals and researchers.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 282
- Erscheinungstermin: 23. April 2018
- Englisch
- Abmessung: 260mm x 183mm x 20mm
- Gewicht: 730g
- ISBN-13: 9780521885379
- ISBN-10: 052188537X
- Artikelnr.: 33766226
- Herstellerkennzeichnung
- Books on Demand GmbH
- In de Tarpen 42
- 22848 Norderstedt
- info@bod.de
- 040 53433511
- Verlag: Cambridge University Press
- Seitenzahl: 282
- Erscheinungstermin: 23. April 2018
- Englisch
- Abmessung: 260mm x 183mm x 20mm
- Gewicht: 730g
- ISBN-13: 9780521885379
- ISBN-10: 052188537X
- Artikelnr.: 33766226
- Herstellerkennzeichnung
- Books on Demand GmbH
- In de Tarpen 42
- 22848 Norderstedt
- info@bod.de
- 040 53433511
Introduction to population diversity and genetic testing: basic concepts
Russ Altman, David Flockhart and David Goldstein; Part I. Critical
Concepts: 1. Introduction to population diversity and genetic testing James
K. Burmester, Ingrid Glurich, Kimberly Pillsbury and Michael D. Caldwell;
2. Genotyping technologies Sharon Marsh and Cristi R. King; 3.
Pharmacokinetics: absorption, distribution, metabolism, excretion Terry
Blaschke; 4. Overview: adverse drug reactions Matthew Nelson; 5. PharmGKB,
a centralized resource for pharmacogenomic knowledge and discovery Li Gong
and Teri E. Klein; 6. DrugBank David S. Wishart; 7. Ethical considerations
for pharmacogenomics: privacy and confidentiality Sandra Lee; 8. Informed
consent in pharmacogenomic research and treatment Mark Rothstein; 9. Legal
trends driving the clinical translation of pharmacogenomics Barbara Evans;
Part II. Therapeutic Areas: 10. Pharmacogenetics of oncologic drugs Uchenna
Njaju and Eileen Dolan; 11. Pharmacogenetics of cardiovascular drugs
Michael Stein and Danny Kurnik; 12. Pharmacogenomics of statin-induced
muscle toxicity Ronald M. Krauss, Russell A. Wilke, Melissa Antonik and
Elenita Kanin; 13. Pharmacogenomics of the drug-induced long QT syndrome
Dan M. Roden, Prince J. Kannankeril, Stefan Kaab and Dawood Darbar; 14.
Pharmacogenetics of diabetes drugs O. H. Klungel and Mark C. H. DeGroot;
15. Pharmacogenetics of respiratory drugs Kelan Tantisira and Scott Weiss;
16. Pharmacogenomics for acid-related gastrointestinal drugs Takahisa
Furuta; 17. Pharmacogenetics of rheumatoid arthritis drugs Robert M.
Plenge, Yvonne C. Lee, Souomya Raychaudhuri and Daniel H. Solomon; 18.
Pharmacogenomics of obstetric drugs David Haas and Jamie Renbarger; 19.
Pharmacogenomics of psychiatric drugs David Mrazek; 20. Pharmacogenomics of
pain and anesthesia drugs Evan Kharasch and Konrad Meissner; 21.
Pharmacogenetics of HIV and antiretroviral drugs Amalio Telenti; 22.
Pharmacogenomics in pediatrics Jennifer A. Lowry and J. Steven Leeder; 23.
Pharmacogenomics in fetal and neonatal medicine Yair Blumenfeld.
Russ Altman, David Flockhart and David Goldstein; Part I. Critical
Concepts: 1. Introduction to population diversity and genetic testing James
K. Burmester, Ingrid Glurich, Kimberly Pillsbury and Michael D. Caldwell;
2. Genotyping technologies Sharon Marsh and Cristi R. King; 3.
Pharmacokinetics: absorption, distribution, metabolism, excretion Terry
Blaschke; 4. Overview: adverse drug reactions Matthew Nelson; 5. PharmGKB,
a centralized resource for pharmacogenomic knowledge and discovery Li Gong
and Teri E. Klein; 6. DrugBank David S. Wishart; 7. Ethical considerations
for pharmacogenomics: privacy and confidentiality Sandra Lee; 8. Informed
consent in pharmacogenomic research and treatment Mark Rothstein; 9. Legal
trends driving the clinical translation of pharmacogenomics Barbara Evans;
Part II. Therapeutic Areas: 10. Pharmacogenetics of oncologic drugs Uchenna
Njaju and Eileen Dolan; 11. Pharmacogenetics of cardiovascular drugs
Michael Stein and Danny Kurnik; 12. Pharmacogenomics of statin-induced
muscle toxicity Ronald M. Krauss, Russell A. Wilke, Melissa Antonik and
Elenita Kanin; 13. Pharmacogenomics of the drug-induced long QT syndrome
Dan M. Roden, Prince J. Kannankeril, Stefan Kaab and Dawood Darbar; 14.
Pharmacogenetics of diabetes drugs O. H. Klungel and Mark C. H. DeGroot;
15. Pharmacogenetics of respiratory drugs Kelan Tantisira and Scott Weiss;
16. Pharmacogenomics for acid-related gastrointestinal drugs Takahisa
Furuta; 17. Pharmacogenetics of rheumatoid arthritis drugs Robert M.
Plenge, Yvonne C. Lee, Souomya Raychaudhuri and Daniel H. Solomon; 18.
Pharmacogenomics of obstetric drugs David Haas and Jamie Renbarger; 19.
Pharmacogenomics of psychiatric drugs David Mrazek; 20. Pharmacogenomics of
pain and anesthesia drugs Evan Kharasch and Konrad Meissner; 21.
Pharmacogenetics of HIV and antiretroviral drugs Amalio Telenti; 22.
Pharmacogenomics in pediatrics Jennifer A. Lowry and J. Steven Leeder; 23.
Pharmacogenomics in fetal and neonatal medicine Yair Blumenfeld.
Introduction to population diversity and genetic testing: basic concepts
Russ Altman, David Flockhart and David Goldstein; Part I. Critical
Concepts: 1. Introduction to population diversity and genetic testing James
K. Burmester, Ingrid Glurich, Kimberly Pillsbury and Michael D. Caldwell;
2. Genotyping technologies Sharon Marsh and Cristi R. King; 3.
Pharmacokinetics: absorption, distribution, metabolism, excretion Terry
Blaschke; 4. Overview: adverse drug reactions Matthew Nelson; 5. PharmGKB,
a centralized resource for pharmacogenomic knowledge and discovery Li Gong
and Teri E. Klein; 6. DrugBank David S. Wishart; 7. Ethical considerations
for pharmacogenomics: privacy and confidentiality Sandra Lee; 8. Informed
consent in pharmacogenomic research and treatment Mark Rothstein; 9. Legal
trends driving the clinical translation of pharmacogenomics Barbara Evans;
Part II. Therapeutic Areas: 10. Pharmacogenetics of oncologic drugs Uchenna
Njaju and Eileen Dolan; 11. Pharmacogenetics of cardiovascular drugs
Michael Stein and Danny Kurnik; 12. Pharmacogenomics of statin-induced
muscle toxicity Ronald M. Krauss, Russell A. Wilke, Melissa Antonik and
Elenita Kanin; 13. Pharmacogenomics of the drug-induced long QT syndrome
Dan M. Roden, Prince J. Kannankeril, Stefan Kaab and Dawood Darbar; 14.
Pharmacogenetics of diabetes drugs O. H. Klungel and Mark C. H. DeGroot;
15. Pharmacogenetics of respiratory drugs Kelan Tantisira and Scott Weiss;
16. Pharmacogenomics for acid-related gastrointestinal drugs Takahisa
Furuta; 17. Pharmacogenetics of rheumatoid arthritis drugs Robert M.
Plenge, Yvonne C. Lee, Souomya Raychaudhuri and Daniel H. Solomon; 18.
Pharmacogenomics of obstetric drugs David Haas and Jamie Renbarger; 19.
Pharmacogenomics of psychiatric drugs David Mrazek; 20. Pharmacogenomics of
pain and anesthesia drugs Evan Kharasch and Konrad Meissner; 21.
Pharmacogenetics of HIV and antiretroviral drugs Amalio Telenti; 22.
Pharmacogenomics in pediatrics Jennifer A. Lowry and J. Steven Leeder; 23.
Pharmacogenomics in fetal and neonatal medicine Yair Blumenfeld.
Russ Altman, David Flockhart and David Goldstein; Part I. Critical
Concepts: 1. Introduction to population diversity and genetic testing James
K. Burmester, Ingrid Glurich, Kimberly Pillsbury and Michael D. Caldwell;
2. Genotyping technologies Sharon Marsh and Cristi R. King; 3.
Pharmacokinetics: absorption, distribution, metabolism, excretion Terry
Blaschke; 4. Overview: adverse drug reactions Matthew Nelson; 5. PharmGKB,
a centralized resource for pharmacogenomic knowledge and discovery Li Gong
and Teri E. Klein; 6. DrugBank David S. Wishart; 7. Ethical considerations
for pharmacogenomics: privacy and confidentiality Sandra Lee; 8. Informed
consent in pharmacogenomic research and treatment Mark Rothstein; 9. Legal
trends driving the clinical translation of pharmacogenomics Barbara Evans;
Part II. Therapeutic Areas: 10. Pharmacogenetics of oncologic drugs Uchenna
Njaju and Eileen Dolan; 11. Pharmacogenetics of cardiovascular drugs
Michael Stein and Danny Kurnik; 12. Pharmacogenomics of statin-induced
muscle toxicity Ronald M. Krauss, Russell A. Wilke, Melissa Antonik and
Elenita Kanin; 13. Pharmacogenomics of the drug-induced long QT syndrome
Dan M. Roden, Prince J. Kannankeril, Stefan Kaab and Dawood Darbar; 14.
Pharmacogenetics of diabetes drugs O. H. Klungel and Mark C. H. DeGroot;
15. Pharmacogenetics of respiratory drugs Kelan Tantisira and Scott Weiss;
16. Pharmacogenomics for acid-related gastrointestinal drugs Takahisa
Furuta; 17. Pharmacogenetics of rheumatoid arthritis drugs Robert M.
Plenge, Yvonne C. Lee, Souomya Raychaudhuri and Daniel H. Solomon; 18.
Pharmacogenomics of obstetric drugs David Haas and Jamie Renbarger; 19.
Pharmacogenomics of psychiatric drugs David Mrazek; 20. Pharmacogenomics of
pain and anesthesia drugs Evan Kharasch and Konrad Meissner; 21.
Pharmacogenetics of HIV and antiretroviral drugs Amalio Telenti; 22.
Pharmacogenomics in pediatrics Jennifer A. Lowry and J. Steven Leeder; 23.
Pharmacogenomics in fetal and neonatal medicine Yair Blumenfeld.